The potential benefits of ProAxsis’ novel ProteaseTag® Active Proteinase 3 Immunoassay will be discussed at the Winter meeting of the British Thoracic Society, which takes place between December 5th-7th at the Queen Elizabeth II Conference Centre, in London. Details of the abstract accepted by the conference review committee are detailed below:
P111: Quantification of Active Proteinase 3 in Sputum Samples Using a Novel Activity-Based Immunoassay
Presenting author: Dr Timothy Ferguson
Session – Understanding complications of cystic fibrosis
Thursday 6th December
Dr David Ribeiro, CEO of ProAxsis, said: “The ProteaseTag® Active Proteinase 3 Immunoassay was recently registered with a European CE Mark, and ProAxsis are delighted to be sharing data on this exciting new addition to the company’s portfolio of immunoassays.”
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com
Related News
ProAxsis (www.proaxsis.com) is undertaking business development activities with Invest Northern Ireland support. Speaking about the plans, Dr David …
In a significant new study, a team at the University of Dundee has shown for the first time that sputum …
ProAxsis were this week delighted to host His Royal Highness, the Duke of York, at their new laboratory …
